Rovin Capital UT ADV Lowers Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Rovin Capital UT ADV decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 28.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,951 shares of the biopharmaceutical company’s stock after selling 2,708 shares during the quarter. Rovin Capital UT ADV’s holdings in Gilead Sciences were worth $642,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. WINTON GROUP Ltd grew its position in shares of Gilead Sciences by 52.9% in the second quarter. WINTON GROUP Ltd now owns 8,800 shares of the biopharmaceutical company’s stock valued at $604,000 after purchasing an additional 3,043 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Gilead Sciences by 0.6% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 85,804 shares of the biopharmaceutical company’s stock valued at $5,887,000 after buying an additional 522 shares during the period. One Capital Management LLC increased its stake in shares of Gilead Sciences by 36.8% during the 2nd quarter. One Capital Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $398,000 after acquiring an additional 1,560 shares during the last quarter. Citizens Financial Group Inc. RI lifted its holdings in shares of Gilead Sciences by 36.1% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 5,984 shares of the biopharmaceutical company’s stock worth $411,000 after acquiring an additional 1,588 shares during the period. Finally, Axxcess Wealth Management LLC boosted its position in shares of Gilead Sciences by 10.2% in the second quarter. Axxcess Wealth Management LLC now owns 19,746 shares of the biopharmaceutical company’s stock worth $1,355,000 after acquiring an additional 1,830 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 1.5 %

Shares of NASDAQ GILD opened at $92.38 on Thursday. The stock has a market capitalization of $115.13 billion, a P/E ratio of 1,026.44, a PEG ratio of 1.27 and a beta of 0.18. The stock’s 50 day moving average price is $91.96 and its two-hundred day moving average price is $83.69. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the business posted $2.29 earnings per share. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. On average, analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were paid a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.33%. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Wall Street Analyst Weigh In

GILD has been the subject of several research analyst reports. Mizuho upped their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Barclays increased their target price on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $87.00 to $113.00 in a research report on Friday, January 10th. BMO Capital Markets raised their price objective on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Finally, Citigroup initiated coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target on the stock. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $97.96.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 8,500 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $91.96, for a total value of $781,660.00. Following the sale, the chief financial officer now directly owns 132,373 shares in the company, valued at approximately $12,173,021.08. This trade represents a 6.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. This represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 453,734 shares of company stock valued at $41,902,086 over the last quarter. Insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.